Janssen Strives For Simplicity In HIV R&D, While Hunting For A Cure
Executive Summary
HIV may be effectively treated and managed with available therapies, but there is still great unmet need for a functional cure and better prevention to stop the epidemic.
You may also be interested in...
J&J's Longtime R&D Head Stoffels To Retire, Raising The Leadership Transition Stakes
Chief scientific officer Paul Stoffels will retire at the end of the year at the same time CEO Alex Gorsky will hand over the top leadership role to Joaquin Duato; no successor has been named.
Sumagen’s World First Killed Whole HIV Vaccine Set For Phase II
After a positive outcome from a US Phase I study, South Korea's Sumagen is stepping closer to the launch of the world's first killed-whole HIV vaccine with potential to both prevent and treat AIDS.
Gilead's Bictegravir Data Could Mean Continued HIV Sector Dominance
Phase II data presented at CROI aren't sufficient to demonstrate statistical superiority over ViiV's Tivicay, but one analyst predicts that a repeat performance in larger Phase III trials could support a superiority claim.